secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001558370-22-003205
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports $150.2M cash; IND for IMM-1-104 expected Q3 2022
--------------------------------------------------------------------

- Net loss Q4 2021: $10.8M ($0.42/share) vs $5.8M ($1.18/share) Q4 2020; full year loss $33.5M.
- Cash and equivalents $150.2M as of Dec 31, 2021; expected cash runway into Q3 2024.
- 2022 GAAP operating expense guidance $55M-$60M; includes non-cash stock-based compensation.
- IMM-1-104 IND filing expected Q3 2022, first patient enrollment in Phase 1 trial Q4 2022.
- IMM-6-415 designated as drug candidate; IND-enabling studies underway, filing expected 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000155837022003205/0001558370-22-003205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000155837022003205/imrx-20220310x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-003205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer